Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis

Zhe Li1 | Zhibao Liu1 | Yuanyuan Wu1 | Huarui Li2 | Zhen Sun3 | Chenggang Han4 | Xiaoling Zhang5 | Jinghua Zhang1

1Department of Oncology, Cangzhou Central Hospital, Cangzhou, China
2Department of Nutriology, Cangzhou Central Hospital, Cangzhou, China
3Department of Thoracic Surgery, Cangzhou Central Hospital, Cangzhou, China
4Department of Radiology, Cangzhou Central Hospital, Cangzhou, China
5Department of Pathology, Cangzhou Central Hospital, Cangzhou, China

Correspondence
Jinghua Zhang, Department of Oncology, Cangzhou Central Hospital, No.16 Xinhua Road, Cangzhou, Hebei, 061000, China.
Email: zhangjinghuazlnk@163.com

Funding information
This work was supported by scientific research project of Hebei health and Family Planning Commission (No.20200321), Grant/Award Number: 202000321

Abstract
Background: To investigate the efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC) through pooling of open published data.

Methods: The electronic databases of Medline (1960–2021.5), Cochrane central register of controlled trials (CENTRAL), EMBASE(1980–2021.5) and Wan fang (1986–2021.5) were systematically searched by two reviewers to identify the relevant clinical trials related to the above subject. The objective response rate (ORR), disease control rate (DCR) and drug relevant adverse reactions were pooled and demonstrated by risk ratio (RR) and 95% confidence interval (95% CI). The statistical heterogeneity across studies was assessed by I-square test. The publication bias was evaluated by Egger’s line regression test and demonstrated by Begg’s funnel plot.

Results: Eleven prospective studies were included in the meta-analysis. The pooled results indicated that the ORR (RR = 1.62, 95% CI: 1.32–2.00, p < 0.05) and DCR (RR = 1.29, 95% CI: 1.18–1.41, p < 0.05) of apatinib alone or apatinib plus paclitaxel/docetaxel was significantly higher than that of the paclitaxel/docetaxel group for advanced NSCLC, respectively. The drug-related adverse reaction was not statistically different between apatinib alone or apatinib plus paclitaxel/docetaxel with regard to the hand-foot syndrome, gastrointestinal reaction, thrombocytopenia, anemia and leukocytopenia (p all > 0.05) except for hypertension (RR = 3.60, 95% CI: 1.26–10.31, p < 0.05). Subgroup analysis also indicated that the hypertension and hand-foot syndrome in apatinib + paclitaxel/docetaxel were higher than that of the paclitaxel/docetaxel group with a statistical difference (p < 0.05).

Conclusions: Apatinib alone or apatinib plus paclitaxel/docetaxel was superior to paclitaxel/docetaxel for ORR and DCR. However, combined treatment with apatinib appears to increase the risk of a patient developing an adverse reaction, especially hypertension and hand-foot syndrome.

KEYWORDS
apatinib, meta-analysis, non-small cell lung cancer, paclitaxel/docetaxel

INTRODUCTION
Cancer epidemiological studies have indicated that lung cancer, especially non-small cell lung cancer (NSCLC), which accounts for 80%–85% all lung carcinoma, is the leading cause of neoplasm-related death globally.1 Due to the lack of specific clinical symptoms, most of the cases are at advanced stages with a poor prognosis and low 5-year survival rate. Chemoradiation, target therapy and immunotherapy2 are the main methods of treatment for advanced stage lung cancer. At present, the first-line treatment for advanced NSCLC patients with positive driver genes is targeted therapy, but the
recommended first-line treatment for advanced NSCLC patients with negative driver genes is platinum-based combination chemotherapy. However, many NSCLC patients cannot tolerate the toxicity of platinum-based combination chemotherapy or drug resistance after several cycles of chemotherapy. Therefore, for patients with advanced NSCLC who fail on first-line chemotherapy, the follow-up treatment appears to be complicated and difficult.

Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). Apatinib is an orally bioavailable, small molecular agent which can inhibit angiogenesis in cancer cells, especially in VEGF-mediated endothelial cell migration and proliferation. As a VEGFR2 tyrosine kinase inhibitor, apatinib can inhibit the VEGF/VEGFR2 signal pathway and reduce the formation of MAPK, so as to inhibit the proliferation of vascular endothelial cells and achieve an antitumor effect. Currently, apatinib has been approved in China for the third-line treatment of advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. It has also shown strong antitumor activity in in vivo and in vitro experiments of cholangiocarcinoma, hepatocellular carcinoma, colorectal cancer and non-small cell lung cancer, bringing new hope for NSCLC patients with negative driver genes. Over the past few years, studies have evaluated the efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced NSCLC. However, the results were inconclusive due to the small sample sizes and other mixed factors that affect the treatment response.

**METHODS**

**Studies identified in the electronic databases**

The electronic databases of Medline (1960–2021.6), Cochrane central register of controlled trials (CENTRAL), EMBASE (1980–2021.5) and Wan fang (1986–2021.5) were systematically searched by two reviewers to identify the relevant clinical trials related to the efficacy and safety of apatinib alone, or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced NSCLC. The studies screening procedure was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement flow chart. The studies were electronically searched using the free terms of “non-small cell lung cancer,” “NSCLC,” “lung cancer,” “lung neoplasm,” “carcinoma of the lung” AND “Apatinib,” “YN968D1,” “Rivoceranib.” Searching of the studies was restricted to human trials, with a language restriction of English and Chinese. All references of the included clinical trials were also reviewed to further identify additional suitable publications.

**Inclusion and exclusion criteria**

The studies initially identified in the databases were further screened by two reviewers independently for evaluation as to whether they fulfilled the inclusion criteria. The study was evaluated in the aspects of study design, comparing patient characteristics, type of intervention, control and outcome (PICO). The study design was limited to prospective clinical studies. Patients: advanced non-small cell lung cancer with pathology or PE-CT confirmation. Intervention: apatinib alone or apatinib plus paclitaxel/docetaxel. Control: paclitaxel/docetaxel. Outcome: response included ORR, DCR and drug relevant adverse reaction. The language was restricted to English and Chinese.

**Methodological quality assessment**

The methodological quality of the included studies was evaluated by two reviewers, respectively according to the Cochrane Reviews Handbook 5.0. Particular attention was paid to the adequate sequence generation, allocation concealment, blinding, incomplete outcome data addressed, free of selective reporting and free of other bias, which mainly demonstrate the methodological quality of the RCT.

**Statistical analysis**

STATA10.0 and RevMan 5.0 statistical software were applied to perform the statistical analysis. The response difference between two groups was expressed by risk ratio (RR) with a 95% confidence interval (CI). Statistical heterogeneity across the included studies was evaluated by I-square (I²) test. The data was combined by random or fixed effect model according to statistical heterogeneity (I² > 50%, random effect model otherwise fixed effect model). The Egger’s line regression test and Begg’s funnel plot were applied to evaluate possible publication bias.

**RESULTS**

**Main characteristics of the studies included**

Eleven prospective studies relevant to the efficacy and safety of apatinib alone, or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced NSCLC were identified and included in the meta-analysis (Figure 1). Four studies compared the efficacy and safety between apatinib alone versus paclitaxel/docetaxel and seven studies compared apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel for the treatment of NCLC. The general characteristics of the included 11 studies are shown in Table 1.

**Methodological quality of the included studies**

The methodological quality of the included studies is shown in the Figure 2. The general methodological quality was
Objective response rate

All the 11 clinical trials included in the study evaluated the ORR between apatinib alone, or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment NSCLC. There was no statistical heterogeneity across the 11 studies ($I^2 = 0.0\%$, $p = 0.931$). Therefore, the ORR was pooled in a fixed effect model with $RR = 1.62$ (95% CI: 1.32–2.00, $p < 0.05$), which demonstrated that ORR in advanced NSCLC patients who received apatinib alone, or apatinib plus paclitaxel/docetaxel, was superior to those who received paclitaxel/docetaxel (Figure 3).

Disease control rate

All 11 studies investigated the disease control rate (DCR). Due to the lack of statistical heterogeneity across the included studies, the DCR was pooled in a fixed effect model with...
| Author            | Year | Age     | Treatment line                  | Apatinib No. Regiment         | Control No. Regiment         | Outcomes                              |
|-------------------|------|---------|---------------------------------|------------------------------|------------------------------|---------------------------------------|
| Ren et al.        | 2017 | 55-56   | NA                              | 25 Apatinib 500 mg/day, orally for 28 days | 25 Docetaxel 75 mg/m² intravenously, every 21 days | ORR, DCR                              |
| Bi et al.         | 2017 | 18-70   | Second-line, recurrence disease | 35 Apatinib 500 mg/day, orally for 28 days | 30 Docetaxel 75 mg/m² intravenously, every 21 days | ORR, DCR, hypertension, hand-foot syndrome, thrombocytopenia, leukocytopenia |
| Tang et al.       | 2019 | 50-58   | Second-line                     | 30 Apatinib 500 mg/day, orally for 21 days | 30 Docetaxel 250 mg intravenously, every 21 days | ORR, DCR                              |
| Chen et al.       | 2017 | 41-79   | NA                              | 42 Apatinib 850 mg/day, orally for 30 days + Paclitaxel 135-145 mg/m² | 42 Paclitaxel 135–145 mg/m², every 21 days | ORR, DCR, gastrointestinal reaction, thrombocytopenia, leukocytopenia |
| Guo and Jing      | 2017 | 33-75   | Second-line, progressed disease  | 19 Apatinib 850 mg/day, orally for 21 days + docetaxel 60 mg/m² intravenously, every 21 days | 21 Docetaxel 60 mg/m² intravenously, every 21 days | ORR, DCR, hypertension, hand-foot syndrome, thrombocytopenia, anemia, leukocytopenia |
| Zhao et al.       | 2019 | 40-70   | NA                              | 32 Apatinib 850 mg/day, orally | 32 Docetaxel 75 mg/m² intravenously, once every 3 weeks | ORR, DCR, gastrointestinal reaction, thrombocytopenia, anemia |
| Hu et al.         | 2020 | 47-75   | Second-line, recurrent disease   | 19 Apatinib 500 mg/day, orally + docetaxel 60 mg/m² intravenously | 20 Docetaxel 60 mg/m² intravenously, once every 3 weeks | ORR, DCR, hypertension, hand-foot syndrome, gastrointestinal reaction, thrombocytopenia, anemia, leukocytopenia |
| Yu et al.         | 2020 | 62(41–74) | Second-line                     | Apatinib 500 mg/day, orally + docetaxel 75 mg/m² intravenously | Docetaxel 75 mg/m² intravenously, once every 3 weeks | ORR, DCR, hypertension, hand-foot syndrome, gastrointestinal reaction, thrombocytopenia, leukocytopenia |
| Pan               | 2020 | 44-79   | NA                              | 27 Apatinib 500 mg/day, orally + docetaxel 75 mg/m² intravenously | 27 Docetaxel 75 mg/m² intravenously, once every 3 weeks | ORR, DCR                              |
| Xie et al.        | 2020 | 35-75   | NA                              | 38 Apatinib 500 mg/day, orally + paclitaxel 75 mg/m² intravenously | 38 Paclitaxel 75 mg/m² intravenously, every 21 days | ORR, DCR, hypertension, gastrointestinal reaction, thrombocytopenia, leukocytopenia |
| Li                | 2020 | NA      | Second-line                     | 60 Apatinib 500 mg/day, orally + paclitaxel 75 mg/m² intravenously | 60 Paclitaxel 75 mg/m² intravenously, every 21 days | ORR, DCR                              |

Abbreviations: NA, not available.
Pooled results indicated that the DCR in apatinib alone or apatinib plus paclitaxel/docetaxel was significantly higher than that of paclitaxel/docetaxel groups for advanced NSCLC (RR = 1.29, 95% CI: 1.18–1.41, p < 0.05) (Figure 4).

**Adverse reactions**

Due to statistical heterogeneity, the drug-related adverse reactions such as hypertension, hand-foot syndrome, gastrointestinal reaction, thrombocytopenia, anemia and ...
leukocytopenia were combined in a random effect model. The pooled results indicated the drug-related adverse reaction was not statistically different between apatinib alone, or apatinib plus paclitaxel/docetaxel in hand-foot syndrome, gastrointestinal reaction, thrombocytopenia, anemia and leukocytopenia ($p_{all} > 0.05$). However, the hypertension risk in the apatinib group was significantly higher than that of the control group ($RR = 3.60$, 95% CI: 1.26–10.31, $p < 0.05$) (Figure 5).

**Subgroup analysis**

The ORR, DCR and drug-related adverse reaction was further analyzed in subgroup analysis according to treatment regimen (apatinib vs. paclitaxel/docetaxel or apatinib + paclitaxel/docetaxel vs. paclitaxel/docetaxel). The pooled results indicated the ORR and DCR were higher in apatinib alone, or the apatinib + paclitaxel/docetaxel group compared to the corresponding control groups ($p < 0.05$) (Table 2). However, the drug-related adverse reaction of hypertension and hand-foot syndrome in apatinib + paclitaxel/docetaxel was higher than that of the paclitaxel/docetaxel group with a statistically significant difference ($p < 0.05$) (Figures 6 and 7).

**Publication bias**

The funnel plot was generally left and right asymmetric for ORR (Figure 8(a)) and DCR (Figure 8(b)). The Egger’s line regression test also indicated obvious publication bias for effect size of ORR ($t = 2.91$, $p = 0.017$) and DCR ($t = 3.372$, $p = 0.008$).

**DISCUSSION**

Eleven prospective clinical studies relevant to the efficacy and safety of apatinib alone, or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced NSCLC, were included in the meta-analysis by pooling of open published data. Of the included 11 trials,
four studies compared the efficacy and safety between apatinib alone versus paclitaxel/docetaxel and seven studies compared the apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of NSCLC. The combined results showed the ORR and DCR of apatinib alone, or apatinib plus paclitaxel/docetaxel were significantly higher than that of the paclitaxel/docetaxel groups for advanced NSCLC, respectively. The drug-related adverse reaction was not statistically different between apatinib alone, or apatinib plus paclitaxel/docetaxel with regard to the hand-foot syndrome, gastrointestinal reaction, thrombocytopenia, anemia and leukocytopenia except for hypertension. These findings indicated apatinib alone, or plus paclitaxel/docetaxel was superior to paclitaxel/docetaxel chemotherapy in treatment response but increased the adverse reaction of hypertension. The subgroup analysis also indicated that the hypertension

| Study ID | RR (95% CI) | Weight |
|----------|-------------|--------|
| Bi JL (2017) | 5.14 (0.66, 40.35) | 1.72 |
| Tang QY (2019) | 1.20 (0.41, 3.51) | 4.43 |
| Guo YJ (2017) | 3.30 (0.14, 76.46) | 0.81 |
| Hu R (2020) | 24.15 (1.52, 383.25) | 1.03 |
| Yu Z (2020) | 4.89 (0.29, 81.53) | 1.00 |
| Xie MQ (2020) | 9.00 (0.50, 161.99) | 0.95 |
| Subtotal (I-squared = 26.8%, p = 0.234) | 3.60 (1.26, 10.31) | 9.94 |
| Hand-foot syndrome | | |
| Bi JL (2017) | 0.64 (0.31, 1.31) | 6.60 |
| Tang QY (2019) | 1.50 (0.27, 8.34) | 2.31 |
| Guo YJ (2017) | 5.50 (0.28, 107.78) | 0.90 |
| Hu R (2020) | 11.55 (0.68, 195.63) | 0.99 |
| Yu Z (2020) | 9.33 (0.59, 146.63) | 1.03 |
| Subtotal (I-squared = 60.9%, p = 0.037) | 2.39 (0.59, 9.63) | 11.84 |
| Gastrointestinal reaction | | |
| Tang QY (2019) | 0.69 (0.39, 1.22) | 7.62 |
| Chen EH (2017) | 0.25 (0.06, 1.11) | 2.87 |
| Zhao J (2019) | 0.40 (0.08, 1.91) | 2.67 |
| Hu R (2020) | 0.99 (0.72, 1.36) | 9.56 |
| Yu Z (2020) | 1.27 (0.30, 5.34) | 3.03 |
| Xie MQ (2020) | 2.00 (0.19, 21.14) | 1.36 |
| Subtotal (I-squared = 28.3%, p = 0.222) | 0.79 (0.52, 1.21) | 27.11 |
| Thrombocytopenia | | |
| Bi JL (2017) | 1.07 (0.32, 3.63) | 3.78 |
| Chen EH (2017) | 0.17 (0.02, 1.33) | 1.70 |
| Guo YJ (2017) | 2.95 (0.91, 9.52) | 3.98 |
| Zhao J (2019) | 0.50 (0.10, 2.54) | 2.52 |
| Hu R (2020) | 1.32 (0.41, 4.18) | 4.06 |
| Xie MQ (2020) | 1.00 (0.06, 15.41) | 1.05 |
| Subtotal (I-squared = 29.1%, p = 0.217) | 1.05 (0.51, 2.16) | 17.09 |
| Anemia | | |
| Guo YJ (2017) | 1.38 (0.43, 4.40) | 4.04 |
| Zhao J (2019) | 0.33 (0.04, 3.04) | 1.53 |
| Hu R (2020) | 0.53 (0.11, 2.56) | 2.64 |
| Subtotal (I-squared = 0.0%, p = 0.418) | 0.84 (0.35, 1.98) | 8.20 |
| Leukocytopenia | | |
| Bi JL (2017) | 0.10 (0.03, 0.31) | 4.34 |
| Chen EH (2017) | 0.33 (0.07, 1.56) | 2.73 |
| Guo YJ (2017) | 1.31 (0.78, 2.17) | 8.15 |
| Hu R (2020) | 1.12 (0.82, 1.55) | 9.56 |
| Xie MQ (2020) | 1.00 (0.06, 15.41) | 1.05 |
| Subtotal (I-squared = 88.1%, p = 0.000) | 0.57 (0.20, 1.60) | 25.82 |
| Overall (I-squared = 46.2%, p = 0.003) | 0.97 (0.73, 1.31) | 100.00 |

**FIGURE 5** The forest plot of adverse reactions for apatinib alone, or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced NSCLC.
and hand-foot syndrome in apatinib + paclitaxel/docetaxel were higher than that of paclitaxel/docetaxel group with statistical difference ($p < 0.05$), but not different between apatinib alone versus paclitaxel/docetaxel treatment cases. Therefore, apatinib alone, or apatinib plus paclitaxel/docetaxel were superior to paclitaxel/docetaxel for ORR and DCR. However, combined treatment with apatinib appears to increase the risk of patients developing an adverse reaction, especially hypertension and hand-foot syndrome.

Lung cancer is the most common malignant tumor with the highest mortality rate in the world. In 2020, there were more than 2,206,771 new cases of lung cancer and

### TABLE 2

| Response/toxicity | Apatinib vs. paclitaxel/docetaxel | ORR | 95% CI | DCR | 95% CI | Hypertension | 95% CI | Hand-foot syndrome | 95% CI | Gastrointestinal reaction | 95% CI | Thrombocytopenia | 95% CI | Anemia | 95% CI | Leukocytopenia | 95% CI |
|------------------|-----------------------------------|-----|--------|-----|--------|--------------|--------|---------------------|--------|-----------------------|--------|----------------|--------|---------|--------|----------------|--------|
|                  | p-value                           |     |        |     |        | p-value      |        |                     |        |                      |        |                |        |         |        |                |        |
| ORR              | 1.69 (1.08–2.64)                  | <0.05 | 1.60 (1.27–2.02) | <0.05 | 1.60 (1.27–2.02) | <0.05 | 1.60 (1.27–2.02) | <0.05 | 1.60 (1.27–2.02) | <0.05 | 1.60 (1.27–2.02) | <0.05 | 1.60 (1.27–2.02) | <0.05 | 1.60 (1.27–2.02) | <0.05 |
| DCR              | 1.36 (1.11–1.68)                  | <0.05 | 1.26 (1.15–1.38) | <0.05 | 1.26 (1.15–1.38) | <0.05 | 1.26 (1.15–1.38) | <0.05 | 1.26 (1.15–1.38) | <0.05 | 1.26 (1.15–1.38) | <0.05 | 1.26 (1.15–1.38) | <0.05 | 1.26 (1.15–1.38) | <0.05 |
| Hypertension     | 1.19 (0.49–7.55)                  | >0.05 | 9.85 (2.45–39.59) | <0.05 | 9.85 (2.45–39.59) | <0.05 | 9.85 (2.45–39.59) | <0.05 | 9.85 (2.45–39.59) | <0.05 | 9.85 (2.45–39.59) | <0.05 | 9.85 (2.45–39.59) | <0.05 | 9.85 (2.45–39.59) | <0.05 |
| Hand-foot syndrome | 0.73 (0.38–1.14)                  | >0.05 | 8.88 (1.69–46.62) | <0.05 | 8.88 (1.69–46.62) | <0.05 | 8.88 (1.69–46.62) | <0.05 | 8.88 (1.69–46.62) | <0.05 | 8.88 (1.69–46.62) | <0.05 | 8.88 (1.69–46.62) | <0.05 | 8.88 (1.69–46.62) | <0.05 |
| Gastrointestinal reaction | 0.64 (0.37–1.11) | >0.05 | 0.84 (0.57–1.23) | >0.05 | 0.84 (0.57–1.23) | >0.05 | 0.84 (0.57–1.23) | >0.05 | 0.84 (0.57–1.23) | >0.05 | 0.84 (0.57–1.23) | >0.05 | 0.84 (0.57–1.23) | >0.05 | 0.84 (0.57–1.23) | >0.05 |
| Thrombocytopenia | 0.81 (0.31–2.16)                  | >0.05 | 1.13 (0.58–2.18) | >0.05 | 1.13 (0.58–2.18) | >0.05 | 1.13 (0.58–2.18) | >0.05 | 1.13 (0.58–2.18) | >0.05 | 1.13 (0.58–2.18) | >0.05 | 1.13 (0.58–2.18) | >0.05 | 1.13 (0.58–2.18) | >0.05 |
| Anemia           | 0.33 (0.04–3.04)                  | >0.05 | 0.95 (0.38–2.36) | >0.05 | 0.95 (0.38–2.36) | >0.05 | 0.95 (0.38–2.36) | >0.05 | 0.95 (0.38–2.36) | >0.05 | 0.95 (0.38–2.36) | >0.05 | 0.95 (0.38–2.36) | >0.05 | 0.95 (0.38–2.36) | >0.05 |
| Leukocytopenia   | 0.38 (0.02–7.43)                  | >0.05 | 1.03 (0.76–1.40) | >0.05 | 1.03 (0.76–1.40) | >0.05 | 1.03 (0.76–1.40) | >0.05 | 1.03 (0.76–1.40) | >0.05 | 1.03 (0.76–1.40) | >0.05 | 1.03 (0.76–1.40) | >0.05 | 1.03 (0.76–1.40) | >0.05 |

### FIGURE 6

The forest plot of toxicity for apatinib alone versus paclitaxel/docetaxel in the treatment of advanced NSCLC
According to the NCCN guideline for NSCLC, platinum-based double drug chemotherapy is generally applied as first-line treatment for advanced NSCLC. However, relevant studies have found that the 5-year survival rate of patients undergoing platinum-based double drug chemotherapy was unsatisfactory with low long-term survival rates and severe drug-related adverse reactions. Paclitaxel and docetaxel are both third generation antitumor drugs, and their antitumor mechanism promotes microtubule polymerization, inhibits depolymerization, and blocks cancer cell synthesis. Paclitaxel or docetaxel are generally recommended for the single drug chemotherapy regimen in patients with advanced NSCLC as maintenance therapy with the response rate of 16%–27%. The mainstream view supports that traditional chemotherapy has reached a bottleneck with regard to tumor treatment response due to dosage restriction and drug-related toxicity. In recent years, with the development of new drugs, targeted therapy immunotherapy and anti-angiogenic treatment have made great progress in improving treatment response, long-term survival and decreasing treatment-related toxicity. Targeted treatment can significantly improve the prognosis of NSCLC patients with positive driver gene mutations, but for NSCLC cases with

| Study ID          | RR (95% CI) | % Weight |
|-------------------|-------------|----------|
| Hypertension      |             |          |
| Guo YJ (2017)     | 3.30 (1.14, 7.64) | 0.56     |
| Hu R (2020)       | 24.15 (1.52, 383.25) | 0.58     |
| Yu Z (2020)       | 4.89 (0.29, 81.53) | 0.82     |
| Xie MQ (2020)     | 9.00 (0.50, 161.59) | 0.59     |
| Subtotal (I-squared = 0.0%, p = 0.774) | 9.85 (2.45, 39.59) | 2.55     |
| Hand-foot syndrome|             |          |
| Guo YJ (2017)     | 5.50 (0.28, 107.78) | 0.56     |
| Hu R (2020)       | 11.55 (0.68, 195.65) | 0.58     |
| Yu Z (2020)       | 9.33 (0.59, 146.63) | 0.82     |
| Subtotal (I-squared = 0.0%, p = 0.935) | 8.88 (1.69, 46.62) | 1.95     |
| Gastrointestinal reaction | | |
| Chen EH (2017)    | 0.25 (0.06, 1.11) | 9.44     |
| Hu R (2020)       | 0.99 (0.72, 1.36) | 18.40    |
| Yu Z (2020)       | 1.27 (0.30, 5.34) | 3.32     |
| Xie MQ (2020)     | 2.00 (0.19, 21.14) | 1.18     |
| Subtotal (I-squared = 31.7%, p = 0.222) | 0.84 (0.57, 1.23) | 32.34    |
| Thrombocytopenia  |             |          |
| Chen EH (2017)    | 0.17 (0.02, 1.33) | 7.08     |
| Guo YJ (2017)     | 2.95 (0.91, 9.52) | 3.36     |
| Hu R (2020)       | 1.32 (0.41, 4.18) | 4.60     |
| Xie MQ (2020)     | 1.00 (0.06, 15.41) | 1.18     |
| Subtotal (I-squared = 49.3%, p = 0.116) | 1.13 (0.58, 2.18) | 16.23    |
| Anemia            |             |          |
| Guo YJ (2017)     | 1.38 (0.43, 4.40) | 4.49     |
| Hu R (2020)       | 0.53 (0.11, 2.55) | 4.60     |
| Subtotal (I-squared = 0.0%, p = 0.332) | 0.95 (0.38, 2.36) | 9.09     |
| Leukocytopenia    |             |          |
| Chen EH (2017)    | 0.33 (0.07, 1.56) | 7.08     |
| Guo YJ (2017)     | 1.31 (0.78, 2.17) | 12.33    |
| Hu R (2020)       | 1.12 (0.82, 1.55) | 17.25    |
| Xie MQ (2020)     | 1.00 (0.06, 15.41) | 1.18     |
| Subtotal (I-squared = 5.1%, p = 0.367) | 1.03 (0.76, 1.40) | 37.85    |
| Overall (I-squared = 38.1%, p = 0.040) | 1.35 (1.08, 1.69) | 100.00   |

**FIGURE 7** The forest plot of toxicity for apatinib alone, or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced NSCLC.
negative driver genes, the target treatment appears to be invalid. Since the 20th century, a series of clinical studies have confirmed that tumor angiogenesis plays an important part in tumor development. The vascular endothelial growth factor (VEGF) pathway plays an important role in the process of tumor angiogenesis. Among the VEGFR family, VEGFR-2 is an important protein, which is considered to be a key molecule related to tumor angiogenesis. VEGF-2 promotes the proliferation of vascular endothelial cells by activating the mitogen activated protein kinase (MAPK) signaling pathway.

Apatinib is an antiangiogenic drug of VEGFR2 tyrosine kinase inhibitor, which can inhibit the VEGF/VEGFR2 signaling pathway and reduce the formation of MAPK, thereby inhibiting the proliferation of vascular endothelial cells and achieving an antitumor effect. At present, apatinib has been approved as third-line treatment for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in China. It has also shown strong antitumor activity in vivo and in vitro in cholangiocarcinoma, hepatocellular carcinoma, colorectal cancer and non-small cell lung cancer, which brings new hope for advanced NSCLC patients with negative driver gene.

In 2019, Yu et al. wrote a meta-analysis relevant to apatinib in the treatment of advanced NSCLC. In their study, the authors found that apatinib was a viable treatment alternative for advanced NSCLC, as it offered a clinically meaningful and statistically significant improvement in PFS, ORR, and DCR. Moreover, therapy with apatinib did not significantly increase toxicity. However, in the study by Yu et al., only five studies were included in the analysis with a small sample size. In our meta-analysis, we systematically searched the relevant electronic databases and finally included 11 prospective clinical studies. The pooled data of the 11 studies included indicated apatinib alone or apatinib plus paclitaxel/docetaxel were superior to paclitaxel/docetaxel for ORR and DCR. However, combined treatment with apatinib appears to place patients more at risk of developing an adverse reaction especially hypertension and hand-foot syndrome. This finding was generally in accordance with the conclusions of Yu et al.

However, the limitation of the present study is obvious. First, although 11 studies were included in the analysis, the sample size was still relatively small with weak statistical power. Second, statistical heterogeneity existed in pooling the drug-related adverse reactions which indicated the results of the included studies were inconsistent with regard to adverse reactions. Third, publication bias was identified for the effect size of ORR and DCR, which may decrease the power of the conclusions. Fourth, the general methodological quality was moderate with most studies with a relatively moderate and high risk of quality bias.

In conclusion, based on the current evidence, apatinib alone, or apatinib plus paclitaxel/docetaxel was superior to paclitaxel/docetaxel for ORR and DCR. However, there appears to be more risk of patients developing adverse reactions, especially hypertension and hand-foot syndrome, in the combined treatment with apatinib. Furthermore, due to the above limitations, the conclusions should be validated by high quality multiple center prospective clinical trials. Regimens containing apatinib have been widely discussed and network meta-analysis are needed to compare the treatment response among different chemotherapy regimens.

ACKNOWLEDGMENT
This work was supported by a scientific research project of Hebei health and Family Planning Commission (No.20200321).

CONFLICT OF INTEREST
The authors declare that there are no conflicts of interest.

ORCID
Zhe Li https://orcid.org/0000-0001-7246-4101

FIGURE 8 The funnel plot for apatinib alone, or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced NSCLC ((a) Objective response rate; (b) disease control rate)
REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

2. Ke W, Zhang L, Dai Y. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thorac Cancer. 2020;11:835–9.

3. Hu Y, Zhou N, Wang R. Apatinib strengthens the anti-tumor effect of cisplatin in thyroid carcinoma through downregulating VEGFR2. J BUON. 2021;26:613–9.

4. Ni N, Wang Z, Yuan G, Sun Y, Zhang R, Li X, et al. An oral small molecule VEGFR2 inhibitor, apatinib, in patients with recurrent or refractory cervical cancer: a real world study. J Oncol. 2020;2020:3852373.

5. Wen S, Shao G, Zheng J, Zeng H, Luo J, Gu D. Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling. Pathol Res Pract. 2019;215:816–21.

6. Zhou K, Zhang JW, Wang QZ, Liu WY, Liu JL, Yao L, et al. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice. Acta Pharmacol Sin. 2019;40:556–62.

7. Zhao J, Yu H, Han T, Wang W, Tong W, Zhu X. A study on the efficacy of recombinant human endostatin combined with apatinib mesylate in patients with middle and advanced stage non-small cell lung cancer. J BUON. 2019;24:2267–72.

8. Hu R, Li T, Hui K, Chen Z, Wang N, Wu X, et al. Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC. Mol Med Rep. 2020;22:3935–43.

9. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Hoboken, NJ: John Wiley & Sons; 2008. [cited 2011 Dec 12]. Available from: http://www.cochrane-handbook.org/

10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

11. Ren XA, Zhang Y, Shao HY. Clinical observation of docetaxel and apatinib in the treatment of patients with advanced non-small cell lung cancer. Chin Med. 2019;17:11–2.

12. Bi JL, Liu HY, Huang Y. Effect of apatinib as single agent on advanced non-small cell lung cancer. J Clin Pulm Med. 2017;22:1474–6.

13. Tang QY, Liao LX, Zeng LZ, Shi DY, Ouyang J, Shi CY. The safety and efficacy evaluation of apatinib in the treatment of advanced non-squamous non-small cell lung cancer during progress period. Contemp Med. 2019;25:32–4.

14. Chen EH, Chen ZC, Chen ML, Che MY. Clinical effect evaluation of Apatinib Mesylate tablets in the treatment of advanced non-small cell lung cancer. Chin Modern Med. 2017;24:91–3.

15. Guo YJ, Jing XH. Efficacy and safety of docetaxel plus apatinib as a second-line treatment for advanced non-squamous non-small cell lung cancer. Chin J Clin Oncol. 2017;44:544–6.

16. Yu Z, Cai X, Xu Z, He Z, Lai J, Wang W, et al. Apatinib plus chemotherapy as a second-line treatment in unsalvageable non-small cell lung carcinoma: a randomized, controlled, multicenter clinical trial. Oncologist. 2020;25:e1640–9.

17. Tan P. Efficacy of apatinib monotherapy in advanced non-small cell lung cancer. Chin J Clin Ration Drug Use. 2020;13:60–2.

18. Xie MQ, Wen B, Tu HX, Song YR. Efficacy of apatinib combined with cisplatin and paclitaxel in the treatment of driver gene wild-type advanced non-squamous non-small cell lung cancer. J Basic Clin Oncol. 2020;33:198–200.

19. Li S. Effect of apatinib combined with paclitaxel injection on patients with non-small cell lung cancer. Contemp Med. 2020;26:175–7.

20. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

21. Shi J, Yang H, Lv T, Pan H, Yang B. Efficacy of platinum drugs in the treatment of elderly patients with advanced non-small cell lung cancer and their effects on prognosis and survival. J BUON. 2020:25:1737–44.

22. Macedo-Perez EO, Morales-Oyarvide V, Mendoza-Garcia VO, Dorantes-Gallareta Y, Flores-Estrada D, Arrieta O. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-cell lung cancer. Cancer Chemother Pharmacol. 2014;74:681–90.

23. Liu H, Wu Y, Wang Z, Song Y. Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with non-small cell lung cancer. Thorac Cancer. 2014;5:337–42.

24. Sheng L, Gao J, Xu Q, Zhang X, Huang M, Dai X, et al. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol. 2021;13:17588359211018537.

25. Li W, Bai R, Cui J. [Targeted therapies for driver gene mutation-positive lung cancer patients with brain metastasis]. Zhongguo Fei Ai Za Zhi. 2019;22:719–26.

26. Shukla NA, Yan MN, Hanna N. The story of angiogenesis inhibitors in non-small-cell lung cancer: the past, present, and future. Clin Lung Cancer. 2020;21:308–13.

27. Cantelmo AR, Dejos C, Kocher F, Hilbe W, Wolf D, Pitcheir A. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. Curr Opin Oncol. 2020;32:44–53.

28. Montanino A, Manzo A, Carillo G, Palumbo G, Esposito G, Sforza V, et al. Angiogenesis inhibitors in small cell lung cancer. Front Oncol. 2021;11:655316.

29. Lin CK, Lin YH, Huang TC, Shi CS, Yang CT, Yang YL. VEGF mediates fat embolism-induced acute lung injury via VEGF receptor 2 and the MAPK cascade. Sci Rep. 2019;9:11713.

30. Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Dev Ther. 2015;9:6075–81.

31. Geng R, Li J. Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2015;16:117–22.

32. Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015;51:223–9.

33. Yu GC, Yang J, Ye B, Xu LL, Li XY, Zheng GR. Apatinib in the treatment of advanced non-small-cell lung cancer: a meta-analysis. Math Biosci Eng. 2019;16:7659–70.

How to cite this article: Li Z, Liu Z, Wu Y, Li H, Sun Z, Han C, et al. Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis. Thorac Cancer. 2021;12:2838–48. https://doi.org/10.1111/1759-7714.14131